Experimental Parkinson’s disease models

Yıl 2018, Cilt: 10 Sayı: 3, 795 - 795, 18.08.2018

Eda Duygu Ipek

https://doi.org/10.37212/jcnos.610154

Öz

Parkinson's disease (PD) is a neurodegenerative disease that develops slowly; however, there is no efficient method of early diagnosis, nor is there a cure. It is characterized by the relatively selective loss of dopaminergic neuronal cells in the substantia nigra pars compacta and the presence of alpha-synuclein aggregation named as Lewy bodies and Lewy neurites in surviving affected neurons. Nigrostriatal dopaminergic neurodegeneration is shared with other parkinsonian disorders, including some genetic forms of parkinsonism, but many of these disorders do not have Lewy bodies. An ideal animal model for PD, therefore, should exhibit age-dependent and progressive dopaminergic neurodegeneration, motor and non-motor dysfunction, and abnormal alpha-synuclein pathology. A wide range of neurotoxic agents are used to induce PD, alterations that are similar with dose observed in human PD. These agents are classified mainly by administration route and the species involved. The toxins that are mainly used in present 6- hydroxydopamine, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, rotenone, paraquat, reserpine, methamphetamine, 3-nitrotyrosine and isoquinoline derivatives (Tieu, 2011; McDowell and Chesselet, 2012; Bezard et al. 2013). In addition, viral mediated expression of human α-synuclein, as well as the inoculation of pathogenic α-synuclein species from Lewy bodies of PD patients, for accurately modelling progressive self-propagating neurodegeneration and genetic LRRK2 models (PARK8 gene mutation) has been used (Jiang and Dickson, 2018). In conclusion, these models are only approximations, each possibly holding a certain degree of relevance. Thus, researchers should select models whose characteristics are most suitable for addressing the experimental question.

Anahtar Kelimeler

Experimental Parkinson’s disease, Neurotoxic agents

Kaynakça

• Bezard E, Yue Z, Kirik D, Spillantini MG. 2013. Animal Models of Parkinson’s Disease: limits and relevance to neuroprotection studies. Movement Dis. 28: 61–70.
• Jiang P, Dickson DW. 2018. Parkinson’s disease: experimental models and reality. Acta Neuropathol 135:13-32.
• McDowell K, Chesselet MF. 2012. Animal models of the non-motor features of Parkinson’s disease. Neurobiol Dis. 46: 597–606.
• Tieu K. 2011. A Guide to Neurotoxic Animal Models of Parkinson’s disease. Cold Spring Harb Perspect Med.. a009316:1-20.